Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy

Show full item record



Permalink

http://hdl.handle.net/10138/304166

Citation

Carpen , T , Saarilahti , K , Haglund , C , Markkola , A , Tarkkanen , J , Hagström , J , Mattila , P & Mäkitie , A 2018 , ' Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy ' , Strahlentherapie und Onkologie , vol. 194 , no. 8 , pp. 759-770 . https://doi.org/10.1007/s00066-018-1309-z

Title: Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy
Author: Carpen, Timo; Saarilahti, Kauko; Haglund, Caj; Markkola, Antti; Tarkkanen, Jussi; Hagström, Jaana; Mattila, Petri; Mäkitie, Antti
Other contributor: University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka
University of Helsinki, Department of Oncology
University of Helsinki, HUS Abdominal Center
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Medicum
University of Helsinki, Korva-, nenä- ja kurkkutautien klinikka
University of Helsinki, Clinicum
















Date: 2018-08
Language: eng
Number of pages: 12
Belongs to series: Strahlentherapie und Onkologie
ISSN: 0179-7158
DOI: https://doi.org/10.1007/s00066-018-1309-z
URI: http://hdl.handle.net/10138/304166
Abstract: To investigate the impact of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV) in oropharyngeal squamous cell carcinoma (OPSCC) and the difference in their role between human papillomavirus (HPV)-positive and HPV-negative patients. The patient cohort consists of 91 OPSCC patients treated with definitive radiochemotherapy or radiotherapy using intensity-modulated radiotherapy (IMRT). All patients had a minimum follow-up of 31 months. Volume measurements were made from computer tomography (CT) scans and HPV status was assessed by p16 immunohistochemistry. The end points were as follows: overall survival (OS), disease-free survival (DFS) and locoregional control (LRC). pGTV was a significant independent prognostic factor for overall survival (OS; p0.020) in p16-negative patients. nGTV of p16-negative tumors had significant prognostic value in all end points in multivariate analyses. High-stage (III-IVc) p16-negative tumors were only associated with significantly poorer OS (p = 0.046) but not with poorer LRC or DFS when compared with the low-stage (I-II) tumors. nGTV of p16-positive tumors was an independent prognostic factor for DFS (p= 0.005) and LRC (p= 0.007) in multivariate analyses. pGTV may serve as an independent prognostic factor in p16-negative patients and nGTV may serve as an independent prognostic factor both in p16-positive and p16-negative patients treated with radiochemotherapy or radiotherapy using IMRT. Tumor volume may have an impact on selecting patients for de-escalation protocols in the future, both in p16-positive and p16-negative patients.
Subject: Human papillomavirus
Survival
Oncology
Radiochemotherapy
Marker
SQUAMOUS-CELL CARCINOMA
HUMAN-PAPILLOMAVIRUS
NECK-CANCER
CONTROL PREDICTIONS
CLINICAL-OUTCOMES
RADIATION-THERAPY
ADVANCED HEAD
CHEMORADIOTHERAPY
SURVIVAL
DELINEATION
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s00066_018_1309_z.pdf 1.400Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record